Pharma Focus Asia

Becton Dickinson Unveils US$36 million (€34 million) R & D Centre in Dublin, Ireland

Introduction:

BD expands operations with US$4.3 million (€4 million) R&D Centre in Dublin and US$32 million (€30) million investment in Enniscorthy manufacturing plant in Ireland.

Features:

The new facility will be dedicated to advancing inaugural on-body injector device, the BD Evolve™ On-Body Injector, aligning with the growing demand for injectable drugs in the pharmaceutical pipeline. 

The new 10,600 sq. ft. R&D facility in Blackrock, accommodating 35 high-tech employees, complements the existing Limerick R&D centre with over 300 personnel.
 
Additionally, it will function as the regional hub for sales, technical service, and corporate functional support teams.

Furthermore, it also expands its operations with a 40,000 sq. ft. facility to manufacture a new medical technology from the Peripheral Intervention business unit. These dual investments will result in the creation of more than 85 new employment opportunities.

Specifications:

Name   Becton Dickinson
Type     New Construction
Budget  US$4.3 million (€4 million) R&D Centre & US$32 million (€30) million Manufacturing Plant

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference